Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA Generic Office Director Uhl Returns From Medical Leave

This article was originally published in The Pink Sheet Daily

Executive Summary

Kathleen Uhl's five-month leave for cancer treatment ends as user fee negotiations move towards formal start.


Related Content

GDUFA II: FDA Prefers A ‘Manageable Number of High-Impact Changes’
GDUFA Stakeholder Deadline May Come After Negotiations Conclude
GDUFA II Negotiations: Contract Manufacturers Gain Seat At Table
FDA Generics Office To Be Managed By Relative Unknown
FDA's Buehler To Join Teva


Related Companies